<DOC>
	<DOC>NCT00168909</DOC>
	<brief_summary>The purpose of this study is to evaluate the effect of alfacalcidol 1 µg daily on the number of fallers in postmenopausal, alendronate-treated, osteopenic or osteoporotic women. primary outcome = number of fallers (patients with at least one locomotor fall incl.mixed falls)</brief_summary>
	<brief_title>Influence of Alfacalcidol on Falls in Osteopenic/Osteoporotic Postmenopausal Women (ALFA Study)</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Bone Diseases, Metabolic</mesh_term>
	<mesh_term>Osteoporosis, Postmenopausal</mesh_term>
	<mesh_term>Alfacalcidol</mesh_term>
	<mesh_term>Hydroxycholecalciferols</mesh_term>
	<criteria>age &gt; 65 years postmenopausal women osteopenia/osteoporosis as defined by WHO criteria Neoplasm or other severe diseases with life expectancy less than one year or expectation of rapid worsening within one year Chronic inflammatory rheumatoid disease Arthritis with continuous pain and influence on locomotion Inflammatory or metabolic bone disease, excluding osteoporosis. Subjects with antiosteoporotic medications who are not willing to switch over to alendronate treatment. Estrogen treatment can be continued 25OHVitamin D3 &lt; 12 ng/ml (12 ng/ml = 30 mmol/L) Systemic corticosteroid treatments of more than one month within previous 12 months Intolerability for alfacalcidol Hypercalcaemia (&gt;2,7 mmol/l) Milk alkali syndrome Uncorrected, severe visual impairments Creatinin &gt; 2.5 mg/dl (&gt;220 µmol/L)</criteria>
	<gender>Female</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2008</verification_date>
	<keyword>osteoporosis</keyword>
	<keyword>frailty</keyword>
	<keyword>falls</keyword>
</DOC>